ImmunityBio‘s patent covers a recombinant SARS-CoV2 vaccine with cross-reactivity against various coronaviruses. The method involves administering the vaccine to elicit an immune response in subjects, targeting different variants of SARS-CoV2. GlobalData’s report on ImmunityBio gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on ImmunityBio, was a key innovation area identified from patents. ImmunityBio's grant share as of February 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.
Cross-reactive sars-cov2 vaccine composition for multiple coronaviruses
See Also:
A recently granted patent (Publication Number: US11911459B2) outlines a method for eliciting an immune response against a coronavirus in a subject by administering a recombinant vaccine composition. The composition includes a first portion encoding a SARS coronavirus nucleocapsid protein fused to an endosomal targeting sequence, and a second portion encoding a SARS virus spike protein. This method aims to generate antibodies that bind to various variants of SARS-CoV2, as well as cytotoxic T cells with cytotoxicity against cells harboring these variants. Additionally, the immune response may involve the generation of memory T cells and memory B cells, enhancing the body's ability to combat the virus.
Furthermore, the patent describes the formulation of the recombinant vaccine composition as a recombinant virus, RNA, or DNA, which can be administered in prime and/or boost administrations. The method also includes generating memory B cells and memory T cells with specificity for different variants of SARS-CoV2 by administering the vaccine composition. By targeting specific proteins of the virus and utilizing regulatory elements to enable their expression, this method aims to enhance the immune response in individuals, potentially providing broader protection against various strains of the coronavirus.
To know more about GlobalData’s detailed insights on ImmunityBio, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
